Positron emission tomography–guided magnetic resonance spectroscopy in Alzheimer disease
- 10 April 2018
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 83 (4) , 771-778
Abstract
Objective: To determine whether the level of metabolites in magnetic resonance spectroscopy (MRS) is a representative marker of underlying pathological changes identified in positron emission tomographic (PET) images in Alzheimer disease (AD).Methods: We performed PET‐guided MRS in cases of probable AD, mild cognitive impairment (MCI), and healthy controls (HC). All participants were imaged by 11C‐Pittsburgh compound B (11C‐PiB) and 18F‐fluorodeoxyglucose (18F‐FDG) PET followed by 3T MRS. PET images were assessed both visually and using standardized uptake value ratios (SUVRs). MRS voxels were placed in regions with maximum abnormality on amyloid (Aβ+) and FDG (hypometabolic) areas on PET scans. Corresponding normal areas were selected in controls. The ratios of total N‐acetyl (tNA) group, myoinositol (mI), choline, and glutamate + glutamine over creatine (Cr) were compared between these regions.Results: Aβ + regions had significantly higher (p = 0.02) mI/Cr and lower tNA/Cr (p = 0.02), whereas in hypometabolic areas only tNA/Cr was reduced (p = 0.003). Multiple regression analysis adjusting for sex, age, and education showed mI/Cr was only associated with 11C‐PiB SUVR (p < 0.0001). tNA/Cr, however, was associated with both PiB (p = 0.0003) and 18F‐FDG SUVR (p = 0.006). The level of mI/Cr was not significantly different between MCI and AD (p = 0.28), but tNA/Cr showed significant decline from HC to MCI to AD (p = 0.001, p = 0.04).Interpretation: mI/Cr has significant temporal and spatial associations with Aβ and could potentially be considered as a disease state biomarker. tNA is an indicator of early neurodegenerative changes and might have a role as disease stage biomarker and also as a valuable surrogate marker for treatment response. Ann Neurol 2018;83:771–778Keywords
Funding Information
- National Institute for Health Research Cambridge Biomedical Research Centre
This publication has 30 references indexed in Scilit:
- Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010Journal of Neuropathology & Experimental Neurology, 2012
- Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adultsNeurology, 2011
- Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake MeasurementsJournal of Nuclear Medicine, 2009
- Alzheimer Disease: Postmortem Neuropathologic Correlates of Antemortem1H MR Spectroscopy Metabolite Measurements1Radiology, 2008
- Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairmentNeurology, 2008
- Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's diseaseNeurobiology of Aging, 2007
- 1H-MR spectroscopy differentiates mild cognitive impairment from normal brain agingNeuroReport, 2001
- Abnormal cerebral metabolite concentrations in patients with probable alzheimer diseaseMagnetic Resonance in Medicine, 1994
- Estimation of metabolite concentrations from localized in vivo proton NMR spectraMagnetic Resonance in Medicine, 1993
- “Autocannibalism” of choline-containing membrane phospholipids in the pathogenesis of Alzheimer's disease—A hypothesisNeurochemistry International, 1985